Mesenchymal Stem Cells Provide Better Results Than Hematopoietic Precursors for the Treatment of Myocardial Infarction

Ana Armín, PhD,*† Carolina Gandía, PhD,*† J. Manuel García-Verdugo, PhD,†‡ Elisa Lledó, PhD,*† César Trigueros, PhD,§ Amparo Ruiz-Saurí, MD, PhD,†‡ María Dolores Miñana, PhD,∥ Pilar Solves, MD, PhD,¶ Rafael Payá, MD, PhD,∥ J. Anastasio Montero, MD, PhD,*† Pilar Sepúlveda, PhD*† Valencia and San Sebastián, Spain

Objectives
The purpose of this study was to compare the ability of human CD34⁺ hematopoietic stem cells and bone marrow mesenchymal stem cells (MSC) to treat myocardial infarction (MI) in a model of permanent left descending coronary artery (LDA) ligation in nude rats.

Background
Transplantation of human CD34⁺ cells and MSC has been proved to be effective in treating MI, but no comparative studies have been performed to elucidate which treatment prevents left ventricular (LV) remodelling more efficiently.

Methods
Human bone marrow MSC or freshly isolated CD34⁺ cells from umbilical cord blood were injected intramyocardially in infarcted nude rats. Cardiac function was analyzed by echocardiography. Ventricular remodelling was evaluated by tissue histology and electron microscopy, and neo-formed vessels were quantified by immunohistochemistry. Chronic local inflammatory infiltrates were evaluated in LV wall by hematoxylin-eosin staining. Apoptosis of infarcted tissue was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay.

Results
Both cell types induced an improvement in LV cardiac function and increased tissue cell proliferation in myocardial tissue and neoangiogenesis. However, MSC were more effective for the reduction of infarct size and prevention of ventricular remodelling. Scar tissue was 17.48±1.29% in the CD34 group and 10.36±1.07% in the MSC group (p<0.001 in MSC vs. CD34). Moreover, unlike MSC, CD34⁺-treated animals showed local inflammatory infiltrates in LV wall that persisted 4 weeks after transplantation.

Conclusions
Mesenchymal stem cells might be more effective than CD34⁺ cells for the healing of the infarct. This study contributes to elucidate the mechanisms by which these cell types operate in the course of MI treatment. (J Am Coll Cardiol 2010;55:2244–53) © 2010 by the American College of Cardiology Foundation

Myocardial infarction (MI) is still one of the main causes of mortality and morbidity in developed countries. In the acute setting, approaches to improve myocardial perfusion range from pharmacological therapies (thrombolysis) to mechanical procedures (primary angioplasty). Recently, several stem cell types have been used in small and large clinical trials in adjunction to conventional therapies for the treatment of MI. First studies of cellular angioplasty were held with bone marrow mononuclear cells (1), and to date all clinical trials have reported similar results, with approximately 8% improvement in global left ventricular (LV) fraction, reduced end-systolic volumes, and improved perfusion in the infarcted area 4 to 6 months after cell transplantation (2,3).

See page 2254

These clinical trials were followed by others with cellular samples enriched for cell progenitors, like circulating blood progenitor cells (2,4) or bone marrow mesenchymal stem cells (MSC) (5,6). However, the enormous variability in the technical procedures used in each study made comparison difficult. For this reason, studies using dif-
different cell types in similar conditions will move the field forward.

In this study, we designed a set of experiments to compare, head-to-head, the ability of 2 human adult stem cell populations—CD34+ cells and MSC—to repair MI. These cell types have become the most clinically relevant for cardiovascular cell therapies. Thus, the data presented here could be useful for the design of more efficient clinical trials with less collateral effects.

**Methods**

All procedures were approved by the Instituto de Salud Carlos III and institutional ethical and animal care committees.

**Figure 1** Characterization of Human CD34+ Umbilical Cord Blood Cells and Bone Marrow MSC

(A) Cell sorting of umbilical cord blood mononuclear fraction with the MACS system (Miltenyi, Bergisch, Germany) and labeling of freshly isolated CD34+ cells with the vital marker CM-Di I, following the manufacturers’ instructions (Molecular Probes, Invitrogen, Eugene, Oregon). Isolated CD34+ cells were photographed at 160× magnification. (B) Mesenchymal stem cells (MSC) in culture (magnification 200×). Retroviral labeling of cultured MSC yielded 95% infection as detected by flow cytometric analysis of green fluorescent protein (GFP)-MSC. Representative flow cytometric analysis of antigenic expression is shown. Shaded histograms represent staining with specific antibodies, and open histograms correspond to matched isotypes. FSC = forward scatter; SSC = side scatter.

**Cells, culture conditions, and retroviral labeling.** Human bone marrow MSC (n = 3) (Inbiomed, San Sebastian, Guipuzcoa, Spain) were cultured following the manufacturers’ instructions and retrovirally labeled with green fluorescent protein as previously reported (7). Transduction efficiency was evaluated by flow cytometry. The CD34+ human umbilical cord blood cells (n = 14) were isolated with the autoMACS system (Miltenyi, Bergisch, Germany) as previously reported (8). For some experiments CD34+ cells were labeled with the vital marker CM-Di I, following the manufacturers’ instructions (Molecular Probes, Invitrogen, Eugene, Oregon).

**Animals.** Nude rats weighing 200 to 250 g (HHI-Foxn1 nu, Charles River Laboratories, Inc., Wilmington, Massachusetts) were used. The initial number of animals included in the study was 90. Animals with fractional shortening (FS) above 35% after MI were excluded. Mortality in all groups due to surgical procedures was approximately 30%. MI and cell transplantation. Permanent ligation of the left coronary artery was performed as previously described (7,9). Seven days later, rats were anesthetized with sevoflurane inhalatory anesthesia (2.5% v/v) followed by IP injection of fentanyl (0.05 mg/kg) and re-opened by a midline sternotomy to perform intramyocardial transplantation (saline, 6 × 10^5 CD34+ cells or 1.2 × 10^6 MSC/animal in 5 injections of 5-μl volume, at 5 points of the infarct border zone with a Hamilton syringe).

**5-bromodeoxyuridine treatment and analysis of proliferating cells.** After cell transplantation, each animal was given daily 0.5-ml IP injection of 5-bromodeoxyuridine (BrdU) (50 mg/kg body weight, IP) for 2 weeks. The BrdU was also given orally in tap water (1 mg/ml) (10). The BrdU-labeled cells in heart tissue were identified with an anti-BrdU antibody (Abcam, Cambridge, Massachusetts). Proliferation index was calculated as a percentage of BrdU-labeled nuclei/total of nuclei identified by 4’-6-diamidino-2-phentanyl staining. Identification of proliferating myofibroblasts or cardiomyocytes was performed by double staining with anti-BrdU antibodies and anti-smooth muscle actin (SMA) or anti-troponin I, respectively (both antibodies from Chemicon International, Harrow, United Kingdom). One thousand SMA+ cells or troponin I+ cells were counted. The SMA+ cells incorporated into vessel structures were not included in the counting.

**Functional assessment by echocardiography.** Transthoracic echocardiography was performed in rats under inhalatory anesthesia (Sevoflurane) with an echocardiographic
Table 1  Echocardiographic Values of Saline, CD34, and MSC Groups

**Baseline MI 2 Weeks 4 Weeks Baseline MI 2 Weeks 4 Weeks Baseline MI 2 Weeks 4 Weeks**

<table>
<thead>
<tr>
<th></th>
<th>Saline (n = 14)</th>
<th>CD34+ Cells (n = 11)</th>
<th>MSC (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AWd</strong></td>
<td>1.25 ± 0.06</td>
<td>1.28 ± 0.17</td>
<td>1.09 ± 0.08</td>
</tr>
<tr>
<td></td>
<td>1.29 ± 0.07</td>
<td>1.19 ± 0.12</td>
<td>1.09 ± 0.08</td>
</tr>
<tr>
<td></td>
<td>1.25 ± 0.09</td>
<td>1.26 ± 0.12</td>
<td>1.07 ± 0.04</td>
</tr>
<tr>
<td></td>
<td>1.29 ± 0.07</td>
<td>1.19 ± 0.12</td>
<td>1.07 ± 0.04</td>
</tr>
<tr>
<td></td>
<td>1.25 ± 0.09</td>
<td>1.26 ± 0.12</td>
<td>1.07 ± 0.04</td>
</tr>
<tr>
<td><strong>LVd</strong></td>
<td>5.83 ± 0.12</td>
<td>6.68 ± 0.16</td>
<td>7.08 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>5.81 ± 0.12</td>
<td>6.70 ± 0.13</td>
<td>7.20 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>5.81 ± 0.12</td>
<td>6.70 ± 0.13</td>
<td>7.20 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>5.81 ± 0.12</td>
<td>6.70 ± 0.13</td>
<td>7.20 ± 0.15</td>
</tr>
<tr>
<td></td>
<td>5.81 ± 0.12</td>
<td>6.70 ± 0.13</td>
<td>7.20 ± 0.15</td>
</tr>
<tr>
<td><strong>LWs</strong></td>
<td>3.43 ± 0.12</td>
<td>4.95 ± 0.38</td>
<td>4.95 ± 0.38</td>
</tr>
<tr>
<td></td>
<td>3.43 ± 0.12</td>
<td>4.95 ± 0.38</td>
<td>4.95 ± 0.38</td>
</tr>
<tr>
<td></td>
<td>3.43 ± 0.12</td>
<td>4.95 ± 0.38</td>
<td>4.95 ± 0.38</td>
</tr>
<tr>
<td></td>
<td>3.43 ± 0.12</td>
<td>4.95 ± 0.38</td>
<td>4.95 ± 0.38</td>
</tr>
<tr>
<td></td>
<td>3.43 ± 0.12</td>
<td>4.95 ± 0.38</td>
<td>4.95 ± 0.38</td>
</tr>
<tr>
<td><strong>PWs</strong></td>
<td>1.99 ± 0.10</td>
<td>2.13 ± 0.17</td>
<td>2.03 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>1.99 ± 0.10</td>
<td>2.13 ± 0.17</td>
<td>2.03 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>1.99 ± 0.10</td>
<td>2.13 ± 0.17</td>
<td>2.03 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>1.99 ± 0.10</td>
<td>2.13 ± 0.17</td>
<td>2.03 ± 0.16</td>
</tr>
<tr>
<td></td>
<td>1.99 ± 0.10</td>
<td>2.13 ± 0.17</td>
<td>2.03 ± 0.16</td>
</tr>
<tr>
<td><strong>EDA</strong></td>
<td>0.30 ± 0.01</td>
<td>0.38 ± 0.02</td>
<td>0.38 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.30 ± 0.01</td>
<td>0.38 ± 0.02</td>
<td>0.38 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.30 ± 0.01</td>
<td>0.38 ± 0.02</td>
<td>0.38 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.30 ± 0.01</td>
<td>0.38 ± 0.02</td>
<td>0.38 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.30 ± 0.01</td>
<td>0.38 ± 0.02</td>
<td>0.38 ± 0.02</td>
</tr>
</tbody>
</table>

All values are mean ± SEM. Anterior wall diastole thickness (AWd), left ventricular diastole internal dimension (LVd), posterior wall diastole thickness (PWd), anterior wall systole thickness (AWs), left ventricular systole internal dimension (LVs), and posterior wall systole thickness (PWs) were calculated as: (AWs – AWd/AWd) × 100. The FS was calculated as: ([LVd – LVDd]/LVDd) × 100. Fractional area change (FAC) was calculated as: ([EDA – ESA]/EDA) × 100.

**Immunohistochemistry and electron microscopy.** Four weeks after implantation, animals were killed, and the hearts were removed and washed with phosphate-buffered saline and fixed in 2% paraformaldehyde or 2% paraformaldehyde/glutaraldehyde for electron microscopy examination. Heart tissue sections were prepared for immunohistochemistry as previously reported (7). For electron microscopy analysis, semi-thin (1.5 μm) and ultrathin (0.05 μm) sections were prepared (7). Muscular and fibrict layer thickness at the infarct border were calculated in transmural LV wall semi-thin sections (n = 5 animals in each group), and values were

![Figure 2](Image)
expressed as a percentage of the total LV wall thickness. Cellular infiltrates were identified on heart tissue after staining of paraffin-embedded sections with hematoxylin/eosin solution (Merk, Darmstadt, Germany).

**Vascular density analysis.** Immunohistochemical detection of vessels was performed with anti-rat CD31 (Chemicon International). Vessels were counted in 10 fields in the peri-infarct zone at 200× and referred as number of vessels/unit area (mm²) with a light microscope and the Image Pro-Plus 5.1 software (Media Cybernetics, Inc., Bethesda, Maryland).

**Morphometry.** The infarct size in the LV was measured in 8 to 12 transverse sections of 14 μm (1 slice each 200 μm of tissue) from apex to base, fixed with 2% paraformaldehyde, and stained with Masson’s trichrome. The fibrotic zone was determined by computer planimetry (Image Pro-Plus 5.1 software, Media Cybernetics, Inc.). Infarct size was expressed as percentage of total LV area and as a mean of all slices from each heart.
Terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Apoptotic cells in heart tissue were detected with the ApopTagPlus Fluorescein In situ Apoptosis Detection Kit (Chemicon International) following the manufacturers’ instructions.

Statistical analysis. Data are expressed as mean ± SEM. All statistical analyses were performed with the SPSS software, version 14.0 (SPSS, Chicago, Illinois). Comparisons between MI and 4 weeks after transplantation in each group were performed with a Wilcoxon W test. Pairwise comparisons between groups at different time points were done with a Mann-Whitney U test. Differences were considered statistically significant at p < 0.05 with a 95% confidence interval.

Results

MSC and CD34+ cells isolation, characterization, and labeling. Purified CD34+ cells were labeled with CM-Di I (Molecular Probes), washed, and used for some in vivo studies. Percentage of labeled cells was more than 99.5% (Fig. 1A). Human bone marrow MSC were expanded, characterized, and labeled with green fluorescent protein by retroviral transduction (Fig. 1B). The percentage of infection was 90 ± 5%. The MSC phenotype was maintained after retroviral labeling as determined by fluorescein-activated cell sorting analysis (Fig. 1B).

Cell transplantation and LV function. Seven days after MI, 6 × 10^5 CD34+ cells or 1.2 × 10^6 MSC were injected intramyocardially. The optimal doses to induce improvement in cardiac function were selected on the basis of previous studies performed by our group and others (7,11). Because CD34+ cells display a higher proliferative capacity in vitro and in vivo, we inoculated half dose with respect to MSC. Furthermore, the dose used for CD34+ cells was sufficient to improve cardiac function as described (11). The echocardiographic parameters from all groups are listed in Table 1. Changes were monitored at baseline, after MI, and after transplantation (2 and 4 weeks). At baseline and after MI, the values of the echocardiographic parameters analyzed were similar among the 3 groups, indicating comparable levels of tissue injury. In cell-treated groups, the improvement in cardiac performance in terms of FS and FAC was observed 2 weeks after transplantation and maintained at least 2 more weeks (Fig. 2). Indeed, 4 weeks after transplantation, FAC was 38.00 ± 2.64% in saline, 48.89 ± 2.41% in the CD34 group, and 49.25 ± 2.16% in the MSC group (p < 0.01 in CD34 and MSC vs. saline). At this time point, FS was 26.00 ± 1.76% in saline, 32.17 ± 1.62% in the CD34 group, and 32.07 ± 1.53% in the MSC group (p < 0.05 in CD34 and MSC vs. saline). The AW thickening was significantly higher in animals transplanted with MSC (28.22 ± 3.27% in saline, 32.99 ± 4.83% in the CD34 group, and 41.35 ± 3.90% in the MSC group; p < 0.05 in MSC vs. saline at 4 weeks), indicating that MSC were more effective in preventing wall thinning and remodeling than CD34+ cells (Fig. 2).

Wall thickness and angiogenesis in CD34 and MSC transplanted animals. Quantification of infarct area in animals from each group revealed that only the MSC group showed a reduced area of fibrous scar tissue (Fig. 3A). Percentage of scar tissue was 18.49 ± 1.58% in the saline group, 17.48 ± 1.29% in the CD34 group, and 10.36 ± 1.07% in the MSC group (p < 0.001 in MSC vs. saline and CD34). Capillary density in the LV wall was significantly greater in the CD34 and MSC groups than in the saline group, as assessed 28 days after implantation (Fig. 3B). Number of vessels/mm² were 567 ± 63 in the saline group, 818 ± 41 in the CD34 group, and 781 ± 35 in the MSC group (p < 0.05 in CD34 vs. saline and MSC vs. saline), confirming the strong ability of MSC and CD34+ cells to induce neoangiogenesis.

Organization of the infarcted tissue in CD34 and MSC groups. Analysis of ultrathin sections from infarct border tissue revealed the marked thinning of ventricular wall in the saline group, due to the fibrotic scar maturation, 4 weeks after treatment (Fig. 4). In contrast, in the CD34 and MSC
groups, animals showed an enlargement of subepicardium and subendocardium cardiomyocyte layers at the same time point. Moreover, the MSC group showed additional bands of myocardial tissue disposed between the fibrotic layers, resulting in further increase of LV wall thickness. Cardiomyocyte muscle layers at the infarct border constituted 45.16 ± 7.23% of the total LV wall thickness in the saline group, 48.41 ± 7.59% in the CD34 group, and 71.0 ± 2.39% in the MSC group (p < 0.05 in MSC vs. CD34 and vs. saline). A comparison between MSC and CD34+ cells migratory capacity in ischemic tissue showed that most CD34+ cells were retained at the site of injection, whereas MSC migrate from the site of implantation to the infarcted zone and were placed in the intermediate fibrotic rim between subepicardium and subendocardium (n = 4) (Fig. 5A). Interestingly, in this layer we observed differences in infarcted tissue organization among groups. The MSC group showed an increase in myofibroblast, as detected by anti-SMA. This myofibroblast layer was thinner in the CD34 group and nearly absent in the saline group (Fig 5B).
expression of collagen I at the infarct zone was reduced in the MSC group but not in the CD34 group (Fig. 5C), indicating the influence of MSC transplantation in extracellular matrix reorganization. Because there is paucity in antibodies able to distinguish myofibroblasts from fibroblasts, electron microscopy analysis was performed to further characterize the fibroblast/myofibroblasts rim (Fig. 5D). Although identical in size, shape, and cytoplasmic structure, myofibroblasts were distinguished from fibroblasts by the presence of abundant myofilaments along the cellular axis (Figs. 5E and 5F). The fact that the MSC group showed increased myofibroblast accumulation and decreased collagen deposition correlated with morphometric studies and pointed to the superior ability of MSC to inverse LV remodelling.

**Tissue regeneration in stem cell-treated animals.** To investigate whether anterior wall thickening and decrease of infarct size was associated with cell proliferation in infarcted tissue, we quantified the number of BrdU+ cells in the LV of BrdU-treated animals (n = 5 in each group). The results showed that MSC induced the highest cell proliferation in myocardial tissue (proliferation index was 12.3 ± 1.5% in the saline group, 17.3 ± 2.5% in the
CD34 group, and 23.2 ± 2.2% in the MSC group; p < 0.05 in MSC vs. saline) (Fig. 6A). In addition, the number of apoptotic cells in the border zone of animals transplanted with MSC was lower than in the other groups (14.43 ± 1.87 in the saline group, 3.20 ± 0.40 in the CD34 group, and 1.20 ± 0.30 in the MSC group; p < 0.01 in CD34 vs. saline and MSC vs. saline) (Fig. 6B). A more exhaustive analysis revealed that most BrdU+ cells showed a fibroblastic morphology and were positively stained with anti-rat SMA antibodies (proliferation index of SMA+ cells was 12.93 ± 1.64% in the control group, 23.81 ± 1.53% in the CD34 group, and 27.36 ± 2.88% in the MSC group; p < 0.05 in CD34 vs. saline and MSC vs. saline) (Fig. 6C). Interestingly, troponin I staining revealed the presence of proliferating cardiomyocytes (cardiomyocyte proliferation index was 0.42 ± 0.28% in the control group, 1.49 ± 0.20% in the CD34 group, and 1.59 ± 0.18% in the MSC group; p < 0.05 in CD34 vs. saline and MSC vs. saline) (Fig. 6D). These proliferating cells were not from human origin, because they were not stained with anti-human nuclei antibodies (not shown). Thus they might be a consequence of paracrine effects exerted by transplanted cells.

Collateral effects induced by stem cell transplantation. It is known that cell transplantation promotes interstitial mononuclear cell infiltration shortly after infusion. However, CD34-treated animals showed higher levels of cell infiltration in comparison with MSC transplanted animals at the latest time points (Fig. 7A). This effect was markedly patent in the epicardial tissue where animals from the CD34 group showed dramatic cell infiltration in comparison with MSC and saline groups (Fig. 7B).

Discussion

Adult stem cell transplantation is an adjuvant treatment to conventional therapies of cardiac ischemic injury. However, the best cell type for each therapeutic application remains to be determined, and more preclinical studies should be...
performed to define the most suitable cell type to be used in the clinical practice (3,12,13).

In this study we demonstrate that MSC transplantation prevents ventricular remodelling and exerts fewer collateral effects than CD34+ cell transplantation. We did not find significant differences in ventricular performance between MSC and CD34+ groups in terms of FS and FAC at 2 or 4 weeks after transplantation. However, echocardiographic parameters related to wall thickening and morphometric/histological studies clearly showed that MSC transplantation prevented the thinning of the LV wall and decreased infarct size more efficiently than CD34+ cell transplantation. The higher sensibility of histological and electron microscopy versus echocardiography to evaluate myocardial architecture and heart geometry in small animals could explain these discrepancies.

General consensus supports the paracrine hypothesis to explain cardiac repair (14–16). The superior ability of MSC to migrate from the site of injection to the infarcted zone, in comparison with CD34+/H11001 MSC, could help them to exert their paracrine effect. Indeed, hypoxia or inflammatory mediators in the ischemic niche could be responsible for MSC migration. For instance, hypoxia induces CXCR4 upregulation via hypoxia inducible factor-1-alpha (17), and a recent work shows that stromal cell-derived factor-1-alpha/CXCR4 interaction is involved in the retention of MSC in the ischemic heart (18). In a similar way, tumor necrosis factor-alpha pre-treatment or overexpression enhances MSC engraftment in cardiac tissue and improves recovery of cardiac function after MI (13,19).

Other phenomena could explain the differences in the wound-healing process observed among groups. MSC transplantation favors myofibroblast proliferation as observed in BrdU experiments. In addition, the myofibroblast middle layer was thicker in animals transplanted with both stem cell types than in the saline group but more markedly in the MSC group, as detected by immunohistochemistry with anti-SMA+ antibodies. Myofibroblasts confer elasticity and contractility to the LV wall and improve wall motion and healing (20,21). After MI, myofibroblasts proliferate to promote infarct healing but die a few days later when the scar is generated in the infarcted region (22). Thus, therapies capable of activating this cell type would be beneficial in the wound repair (22,23).

Another important observation is the ability of MSC to reduce collagen I deposition at the infarct zone. Although we could not quantify it, previous works have shown the influence of MSC transplantation in attenuation of fibrosis and collagen I deposition (24–26).

Conclusions

We have demonstrated that CD34+ cells—their therapeutic potential notwithstanding—induce a chronic cell infiltration of cardiac tissue and do not efficiently prevent LV remodelling. Mesenchymal stem cells, however, migrate to the site of infarction, potentiate the healing of the infarct, and control the remodelling process. Thus, the latter seems to be more appropriate to use in clinical practice for the treatment of MI.

Acknowledgments

The authors are indebted to Dr. A. Chapel for the gift of the pSF-G13 cell line. The authors thank A. Hernández and E. Lafuente from the Service of Confocal microscopy at Centro de Investigación Príncipe Felipe for technical assistance, and M. Llop and M. Soriano for electron microscopy micrographs.

Reprint requests and correspondence: Dr. Pilar Sepúlveda, Fundación para la Investigación Hospital Universitario La Fe, Regenerative Medicine and Heart Transplantation Unit, Avda Campanar 21, Valencia 46009, Spain. E-mail: pilar.sepuveda@uv.es. OR Dr. J. Anastasio Montero, Hospital Universitario La Fe, Servicio de Cirugía Cardiaca, Avda Campanar 21, Valencia 46009, Spain. E-mail: montero_jos@gva.es.

REFERENCES


Key Words: hematopoietic precursors • left ventricular function • mesenchymal stem cells • myocardial infarction • paracrine factors.